Skip to main content

Table 2 Patient and tumor characteristics

From: RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study

 ITT
N = 55
ITT2
N = 35
n %n %
GenderMale30 (55)22 (63)
Female25 (45)13 (37)
AgeMean6161
SD10.59.4
Range53–6951–69
Primary tumor present at baseline 16 (29)12 (34)
ECOG PS0 vs 155 (100)35 (100)
Stage at initial diagnosisI1 (2)1 (3)
II2 (4)0
III12 (22)8 (23)
IV40 (73)26 (74)
Number of site (s) involved112 (22)8 (23)
220 (36)15 (43)
>223 (42)12 (34)
Prior therapies received
Fluoropyrimidines 55 (100)35 (100)
Oxaliplatin 53 (96)35 (100)
Irinotecan 55 (100)35 (100)
VEGF inhibitorsa 53 (96)34 (97)
EGFR inhibitorsb 27 (49)20 (57)
  1. Abbreviations: SD Standard deviation, ECOG PS Eastern Cooperative Oncology Group Performance Status, EGFR Epidermal growth factor receptor, VEGF Vascular endothelial growth factor
  2. aVEGF bevacizumab and aflibercept
  3. bEGFR cetuximab and panitumumab